Polyethylene Glycol (Movicol) is More Potent Than Lactulose
Polyethylene glycol (PEG) is the stronger and more effective osmotic laxative compared to lactulose, with superior efficacy in increasing stool frequency, improving stool consistency, and causing fewer side effects. 1
Evidence Hierarchy and Strength of Recommendation
The 2023 AGA-ACG guidelines provide clear guidance on this comparison:
- PEG receives a STRONG recommendation with moderate certainty of evidence for chronic idiopathic constipation 1
- Lactulose receives only a CONDITIONAL recommendation with very low certainty of evidence, and only for patients who have failed or are intolerant to over-the-counter therapies 1
This hierarchical positioning in the guidelines directly answers your question: PEG is positioned as first-line therapy while lactulose is relegated to second-line status.
Direct Comparative Evidence
Multiple high-quality studies demonstrate PEG's superiority:
In pediatric populations: A 2010 Cochrane meta-analysis of 10 randomized controlled trials found that PEG significantly outperformed lactulose across multiple outcomes 2:
- Higher stool frequency per week
- Better stool consistency
- Superior relief of abdominal pain
- Less need for additional laxative products
Recent pediatric RCTs confirm this: A 2021 study showed PEG 3350 produced significantly higher weekly stool frequency starting from week 1 (median 8 vs 7 stools, p<0.01) and maintained this advantage through 4 weeks 3. Similarly, a 2019 multicenter RCT found PEG produced more defecations per week (7.9 vs 5.7, p=0.008) with fewer side effects 4.
In faecal impaction: PEG achieved 92% disimpaction success as monotherapy, and during maintenance therapy, 23% of children reimpacted on lactulose versus 0% on PEG (p=0.011) 5.
Side Effect Profile: PEG Wins
Lactulose causes significantly more gastrointestinal side effects 1:
- Bloating and flatulence are dose-dependent and "very common" with lactulose
- These symptoms are often limiting in clinical practice, particularly in patients with pre-existing bloating
- The 2019 pediatric study found more patients with side effects on lactulose (23 vs 15, p=0.02), predominantly bloating and abdominal pain 4
PEG's side effects (bloating, abdominal discomfort, cramping) occur but are generally better tolerated and less frequent 1.
Practical Dosing Considerations
PEG (Movicol):
- Initial dose: 17 g daily 1
- Titrate per symptom response
- No clear maximum dose
- Durable response demonstrated over 6 months 1
Lactulose:
- Initial dose: 15 g daily 1
- FDA-approved dosing: 10-20 g (15-30 mL) daily, up to 40 g if needed 6
- Bloating/flatulence worsen with dose escalation, limiting titration 1
Clinical Algorithm
- First-line: Start with PEG 17 g daily for chronic constipation
- If PEG fails or is not tolerated: Consider lactulose 15 g daily
- Special circumstance: Lactulose is the only osmotic agent studied in pregnancy 1
Important Caveats
- The very low quality of evidence for lactulose stems from only 2 RCTs conducted over 40 years ago in elderly nursing home patients 1
- PEG's evidence base is substantially more robust with multiple recent, well-designed trials
- Cost is similar for both agents (<$50/month) 1
Bottom line: When choosing between these osmotic laxatives based on potency and overall clinical effectiveness, PEG is objectively the stronger choice, supported by both guideline recommendations and comparative trial data.